论文部分内容阅读
To the editor:We read with interest the article of Zheng et al1 on sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM).rnNephrologists are interested in the treatment of acute renal failure (ARF) in the course of MM because the survival of patients is affected by the recovery of normal renal function,not only for the specific complications of ARF but also for the reduced opportunities for access to more effective drug treatments.To date,the evolution of renal disorders associated with monoclonal light chains in MM remain poorly defined.